91Â鶹ÌìÃÀÖ±²¥

Christopher Nevala-Plagemann
( out of 81 reviews )

Christopher Nevala-Plagemann, MD, MSCI

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Gastrointestinal
Salt Lake City
801-585-0250

Sugar House Health Center

Salt Lake City
801-581-2000

  • Chris Nevala-Plagemann is an Assistant Professor of Oncology in the Department of Medicine at the Huntsman Cancer Institute at the University of Utah. He is a board certified medical oncologist with a clinical focus on patients with gastrointestinal cancers.

    Dr. Nevala-Plagemann’s current research is focused on utilizing information contained in large real-world databases to find better ways to treat patients with gastrointestinal cancers using currently available treatments. He is also actively involved in clinical trials at HCI with a goal of identifying novel ways to improve the lives of his patients.

    Prior to joining faculty at HCI, Dr. Nevala-Plagemann received his medical degree from the University of Minnesota. During his medical training he worked in a lab at the University of Minnesota Stem Cell institute where his research focused on gene editing using the CRISPR/cas9 system. Following his undergraduate medical training he moved to Salt Lake City where he completed his internal medicine residency, medical oncology fellowship, and a Master of Science in Clinical Investigation degree here at the University of Utah.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 81 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 03, 2024
    SUGAR HOUSE HEALTH CENTER

    He took the time to listen to us and explains situations so we understand.

    September 19, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr Chris is simply the best, we are so grateful that he is our doctor. His knowledge and care has been outstanding in every way throughout my treatment.

    September 13, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Nevada was wonderful in explaining my diagnosis in as great of detail as we wanted. He explained the pro's and cons of every decision and what the risk/benefits were. He explained the options available to us and clearly explained his recommendations and how they were working together as a medical community to provide the very best possible long term solution. His understanding and calm approach comforted our concerns and fears.

    September 12, 2024
    SUGAR HOUSE HEALTH CENTER

    Just starting this journey and feel that I am in very capable hands with DR Nevala and his team

    September 11, 2024
    SUGAR HOUSE HEALTH CENTER

    Dr. Nevala is a GREAT physician. He has a wonderful manner about him, puts the patient at ease during a very trying time. He takes the time to explain the what, how, and why of the procedures and processes. If you are lucky enough to be treated by him and his team, you are in good hands.

    September 11, 2024
    SUGAR HOUSE HEALTH CENTER

    A great listener. Answers questions thoroughly and compassionately.

    July 25, 2024
    SUGAR HOUSE HEALTH CENTER

    this is the Dr you'd want if you ever needed chemo

    July 16, 2024
    HUNTSMAN CANCER CENTER

    Dr. Nevala treated me very well. He listened, answered all my questions and explained the option for my cancer. He was very positive and I left his office feeling very optimistic about my future.

    July 05, 2024
    SUGAR HOUSE HEALTH CENTER

    Very compassionate and caring

    See More Patient Comments

  • Chris Nevala-Plagemann is an Assistant Professor of Oncology in the Department of Medicine at the Huntsman Cancer Institute at the University of Utah. He is a board certified medical oncologist with a clinical focus on patients with gastrointestinal cancers.

    Dr. Nevala-Plagemann’s current research is focused on utilizing information contained in large real-world databases to find better ways to treat patients with gastrointestinal cancers using currently available treatments. He is also actively involved in clinical trials at HCI with a goal of identifying novel ways to improve the lives of his patients.

    Prior to joining faculty at HCI, Dr. Nevala-Plagemann received his medical degree from the University of Minnesota. During his medical training he worked in a lab at the University of Minnesota Stem Cell institute where his research focused on gene editing using the CRISPR/cas9 system. Following his undergraduate medical training he moved to Salt Lake City where he completed his internal medicine residency, medical oncology fellowship, and a Master of Science in Clinical Investigation degree here at the University of Utah.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Graduate Training Clinical Investigation - University of Utah School of Medicine M.S.
    Fellowship Hematology/Oncology - University of Utah School of Medicine Fellow
    Residency Internal Medicine - University of Utah School of Medicine Resident
    Professional Medical Medicine - University of Minnesota Medical School M.D.
    Undergraduate Biology - Luther College B.A.

    Selected Publications

    Journal Article

    1. Smith JT, Sama S, Florou V, Nevala-Plagemann C, Garrido-Laguna I (2023). Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: case report. J Gastrointest Oncol, 14(6), 2637-2643. ()
    2. Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna I (2022). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clin Cancer Res, 29(17), 3408-3417. ()
    3. Nevala-Plagemann C, Sama S, Ying J, Shen J, Haaland B, Florou V, Garrido-Laguna I (2022). A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 21(3), 257-264. ()
    4. Miotke L, Nevala-Plagemann C, Ying J, Florou V, Haaland B, Garrido-Laguna I (2022). Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. BMC Cancer, 22(1), 1054. ()
    5. Nevala-Plagemann C, Iyengar S, Trunk AD, Pappas L, Haaland B, Garrido-Laguna I (2022). Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 20(3), 268-275. ()
    6. Trunk A, Braithwaite M, Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna I (2020). Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. J Natl Compr Canc Netw, 20(2), 144-150. ()
    7. Baron MK, Wang X, Nevala-Plagemann C, Moser JC, Haaland B, Garrido-Laguna I (2021). Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas, 50(6), 796-802. ()
    8. Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna I (2021). Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. J Natl Compr Canc Netw, 19(5), 478-482. ()
    9. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4. ()
    10. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol, 17(2), 108-123. ()
    11. Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open, 4(4), e000539. ()
    12. Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 3(5), e000386. ()
    13. Nevala-Plagemann C, Lee C, Tolar J (2015). Placenta-based therapies for the treatment of epidermolysis bullosa. Cytotherapy, 17(6), 786-795. ()

    Review

    1. Iyengar S, Nevala-Plagemann C, Garrido-Laguna I (2021). Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. [Review]. Ther Adv Med Oncol, 13, 17588359211045861. ()
    2. Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna I (2021). Emerging Treatment Strategies in Metastatic Pancreatic Cancer. [Review]. Pancreas, 50(6), 773-787. ()
    3. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. [Review]. Nat Rev Clin Oncol, 17(2), 108-123. ()

    Case Report

    1. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4. ()
    2. Nevala-Plagemann C, Powers P, Mir-Kasimov M, Rose R (2019). A Fatal Case of Septic Shock Secondary to Acinetobacter Bacteremia Acquired from a Platelet Transfusion. Case Rep Med, 2019, 3136493. ()

  • News & Podcasts

    Huntsman Cancer Institute News

  • Clinical Trials